GlassScriptPhysician profile
Mika Westfall
NPI 1417792003
$1,428.36
in general payments reported to CMS, 2019-2025
26 companies · $1,085 in 2025
The $1,085 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $344 · 2025: $1,085.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $985 · Education: $443.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $985.45 |
| Education | $442.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $226.74 | 2024-2025 | Erleada, Rybrevant, Tecvayli |
| Daiichi Sankyo INC. | $163.05 | 2025 | Enhertu, Injectafer |
| Abbvie INC. | $104.78 | 2024-2025 | |
| Seagen INC. | $99.99 | 2025 | |
| Incyte Corporation | $95.95 | 2025 | |
| Novartis Pharmaceuticals Corporation | $80.38 | 2024-2025 | |
| Aveo Pharmaceuticals, INC. | $74.99 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $69.98 | 2024-2025 | Enhertu, Imfinzi |
| Exelixis INC. | $57.71 | 2025 | Cabometyx |
| Legend Biotech USA INC. | $51.49 | 2025 | Carvykti |
| Merck Sharp & Dohme LLC | $50.00 | 2025 | Keytruda, Welireg |
| Pfizer INC. | $43.33 | 2024-2025 | |
| Tersera Therapeutics LLC | $38.52 | 2025 | Zoladex |
| Bayer Healthcare Pharmaceuticals INC. | $32.14 | 2025 | |
| Array Biopharma INC | $31.63 | 2025 | Tukysa, Braftovi, Mektovi |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Recordati_rare_diseases_inc. | $29.08 | 2025 | Panhematin |
| Takeda Pharmaceuticals U.S.A., INC. | $27.05 | 2025 | |
| Kite Pharma, INC. | $22.81 | 2025 | Yescarta |
| Geron Corporation | $19.33 | 2025 | Rytelo |
| Cycle Pharmaceuticals INC | $19.05 | 2025 | Phyrago |
| Beigene USA, INC. | $16.43 | 2025 | Brukinsa |
| Celgene Corporation | $15.59 | 2024 | Reblozyl |
| Taiho Oncology, INC. | $15.39 | 2024 | |
| Beone Medicines USA, INC. | $14.71 | 2025 | Tevimbra |
| Coherus Oncology, INC. | $14.21 | 2024 | |
| Alexion Pharmaceuticals, INC. | $14.03 | 2024 | Ultomiris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mika Westfall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.